Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bridges

Showing results (251-260 of 403) with videos related to

Pageof 41
Sort By:
The Lancet. Haematology|May 4, 2020
Approaches to measure paediatric chemotherapy-induced peripheral neurotoxicity: a systematic reviewEllen M Lavoie Smith, Clare Kuisell, Grace A Kanzawa-Lee, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2010
Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: development of a potent and highly selective M1 PAMThomas M Bridges, J Phillip Kennedy, Meredith J Noetzel, et al.
Oral Health & Preventive Dentistry|September 9, 2014
Efficacy of instruments measuring oral health literacy: a systematic reviewDivya S Parthasarathy, Colman P J McGrath, Susan M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|February 27, 2017
Continued optimization of the M<sub>5</sub> NAM ML375: Discovery of VU6008667, an M<sub>5</sub> NAM with high CNS penetration and a desired short half-life in rat for addiction studiesKevin M McGowan, Kellie D Nance, Hykeyung P Cho, et al.
Drug News & Perspectives|June 4, 2010
The antipsychotic potential of muscarinic allosteric modulationThomas M Bridges, Evan P LeBois, Corey R Hopkins, et al.
Elife|September 15, 2022
Solute exchange through gap junctions lessens the adverse effects of inactivating mutations in metabolite-handling genesStefania Monterisi, Johanna Michl, Alzbeta Hulikova, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 13, 2015
A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In VivoAnna L Blobaum, Frank W Byers, Thomas M Bridges, et al.
British Journal of Haematology|March 1, 1986
Lymphocytes from patients receiving lithium do not inhibit CFU-C growthA E Irvine, A D Crockard, Z R Desai, et al.
Chemical Reviews|February 17, 2016
Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsCraig W Lindsley, Kyle A Emmitte, Corey R Hopkins, et al.
Bioorganic & Medicinal Chemistry Letters|December 11, 2012
Development of an in vivo active, dual EP1 and EP3 selective antagonist based on a novel acyl sulfonamide bioisostereJason D Downey, Sam A Saleh, Thomas M Bridges, et al.
Pageof 41

Showing results (251-260 of 403) with videos related to

Sort By:
Pageof 41
The Lancet. Haematology|May 4, 2020
Approaches to measure paediatric chemotherapy-induced peripheral neurotoxicity: a systematic reviewEllen M Lavoie Smith, Clare Kuisell, Grace A Kanzawa-Lee, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2010
Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: development of a potent and highly selective M1 PAMThomas M Bridges, J Phillip Kennedy, Meredith J Noetzel, et al.
Oral Health & Preventive Dentistry|September 9, 2014
Efficacy of instruments measuring oral health literacy: a systematic reviewDivya S Parthasarathy, Colman P J McGrath, Susan M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|February 27, 2017
Continued optimization of the M<sub>5</sub> NAM ML375: Discovery of VU6008667, an M<sub>5</sub> NAM with high CNS penetration and a desired short half-life in rat for addiction studiesKevin M McGowan, Kellie D Nance, Hykeyung P Cho, et al.
Drug News & Perspectives|June 4, 2010
The antipsychotic potential of muscarinic allosteric modulationThomas M Bridges, Evan P LeBois, Corey R Hopkins, et al.
Elife|September 15, 2022
Solute exchange through gap junctions lessens the adverse effects of inactivating mutations in metabolite-handling genesStefania Monterisi, Johanna Michl, Alzbeta Hulikova, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 13, 2015
A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In VivoAnna L Blobaum, Frank W Byers, Thomas M Bridges, et al.
British Journal of Haematology|March 1, 1986
Lymphocytes from patients receiving lithium do not inhibit CFU-C growthA E Irvine, A D Crockard, Z R Desai, et al.
Chemical Reviews|February 17, 2016
Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsCraig W Lindsley, Kyle A Emmitte, Corey R Hopkins, et al.
Bioorganic & Medicinal Chemistry Letters|December 11, 2012
Development of an in vivo active, dual EP1 and EP3 selective antagonist based on a novel acyl sulfonamide bioisostereJason D Downey, Sam A Saleh, Thomas M Bridges, et al.
Pageof 41